Form 4: Nurix Therapeutics' Chief Legal Officer Reports Stock Transactions
SEC Form 4 Filing
Christine Ring, Chief Legal Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.
Summary
- On July 30, 2024, Christine Ring, the Chief Legal Officer of Nurix Therapeutics, reported transactions involving the company's common stock and restricted stock units (RSUs).
- Ring acquired 1,924, 2,000 and 3,750 shares of common stock through the vesting of RSUs.
- Simultaneously, she disposed of 2,920 shares of common stock at a weighted average price of $20.6677 to cover tax withholding obligations related to the vesting of RSUs.
- These sales were mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person.
- Following these transactions, Ring beneficially owns 24,592 shares of common stock and varying amounts of RSUs that will vest over time.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Positives
- The vesting of RSUs indicates that the reporting person is meeting the service requirements of the equity incentive plan.
- The 'sell to cover' arrangement simplifies the tax obligations for the reporting person.
Future Outlook
The document does not contain any specific forward-looking statements or guidance regarding the company's future performance.
Industry Context
Form 4 filings are a routine part of the US stock market and are required by the SEC to provide transparency into the transactions of company insiders. This filing indicates the transactions of the Chief Legal Officer of Nurix Therapeutics.
Stakeholder Impact
- Shareholders are informed about the insider transactions of the Chief Legal Officer.
- The transactions have a minimal impact on the overall market capitalization of the company.
Key Dates
| Date | Description |
|---|---|
| 04/30/2022 | First quarterly vesting increment for 1,924 RSUs. |
| 07/30/2023 | First quarterly vesting increment for 2,000 RSUs. |
| 07/30/2024 | Date of the reported transactions: acquisition of shares through RSU vesting and sale of shares to cover tax obligations; first quarterly vesting increment for 3,750 RSUs. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.